ClinicalTrials.gg
TerminatedNCT04652518Updated Jun 23, 2026Results posted

LYT-100 in Post-acute COVID-19 Respiratory Disease

A Phase 2 interventional study of LYT-100 and Placebo in Covid19 and Post-acute COVID-19 Respiratory Disease, sponsored by PureTech. Terminated at 31 sites in 8 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by PureTech · Phase 2, Interventional, and Treatment

Why this study was terminated
Part A of the study was completed; Part B of the study was terminated

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
185
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
503rd of 1,321
185 · median 91
Started
2020
with 817 others
Phase 2
349 of 1,859
14 open now
Registered
831st of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 503rd largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 831st registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted in two parts, A and B. Part A is a randomized, double-blind, parallel arm study to evaluate the safety and efficacy of LYT-100 compared to placebo in adults with post-acute COVID-19 respiratory complications. Part B is an Open Label Extension (OLE) study for patients who complete Part A.

Read the detailed description

Part A of this study is a randomized, double-blind, parallel arm study being conducted at approximately 35 centers globally to evaluate the safety and efficacy of LYT-100 compared to placebo in 168 adults with post-acute COVID-19 respiratory complications who were treated with mechanical ventilation, extracorporeal membrane oxygenation, non-invasive ventilation (eg CPAP or BiPAP), high-flow nasal oxygen therapy or any other means of oxygen administration in the hospital for at least 1 day and have required only low flow nasal oxygen or no oxygen supplementation for at least 72 hours prior to screening. LYT-100 or placebo will be taken daily for up to 91 days with the primary outcome of change in distance walked on the six-minute walk test performed in line with the American Thoracic Society Respiratory Society Guidelines assessed at Day 91. Secondary endpoints, including pharmacokinetics, inflammatory biomarkers, imaging, and patient-reported outcomes of dyspnea and the 36-Item Short Form Health Survey will also be evaluated.

The second part of the study, Part B, is an open-label extension in which eligible patients who completed Part A will be enrolled and treated with open-label LYT-100 for an additional 91 days. The primary endpoint for Part B of the study is to assess the longer-term safety, tolerability, and efficacy of LYT-100 through up to 182 days of treatment.

03

Conditions studied

  • Covid19
  • Post-acute COVID-19 Respiratory Disease

Keywords

  • COVID-19 Respiratory Disease
  • novel coronavirus
  • respiratory complications
  • SARS-CoV-2
  • post acute
  • lung fibrosis
  • interstitial lung disease
  • long COVID
  • long haul COVID
  • Post-acute COVID-19 Respiratory Disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Positive result of a molecular RT-qPCR diagnostic test or SARS-CoV-2 RNA result from a clinical specimen deemed clinically associated with the current episode of illness, warranting hospital admission as per investigator's judgement, or previously hospitalized (central and/or local laboratory COVID-19 test results are accepted from any biological material source)
  • Hospitalization for COVID-19 respiratory disease and treated with supplemental oxygen (including MV, ECMO or any other means of oxygen administration) in hospital for at least 1 day
  • COVID-19 pneumonia findings on imaging (chest X-ray or CT Scan) with a minimum of two lung lobes involvement
  • Able to bear weight and ambulate a minimum of 10 m distance (use of inhaled oxygen permitted)
  • Shortness of breath ≥ grade 3 on mBDS dyspnea scale and not requiring MV, ECMO, NIV, and/or HFNO (nasal O2 is allowed) for at least 72 hours before screening

Key Exclusion Criteria:

  • Pre-existing chronic respiratory condition(s), obstructive or restrictive, for which the patient is actively taking concomitant medication are excluded. Patients with history of Idiopathic Pulmonary Fibrosis (IPF), lung cancer, pulmonary arterial hypertension, other interstitial lung diseases, severe cardiac insufficiency (grade IV) are excluded irrespective of whether they are actively being medicated for those conditions or not.
  • Pre-existing co-morbid conditions preventing outcome assessments, e.g., neurological, medical, orthopedic injury/disability, disease or condition that would prevent ability to transfer and walk for 6 minutes, prior to confirmed COVID-19 diagnosis
  • Unstable angina or myocardial infarction in the last month prior to screening
  • Patients on MV, ECMO, NIV, and/or HFNO within the last 72 hours prior to screening
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
185 participants (actual)

Study arms

  • Experimental
    LYT-100

    LYT-100 taken orally twice a day (BID) for 91 days

    Drug: LYT-100

  • Placebo comparator
    Placebo

    Placebo matching LYT-100 taken orally BID for 91 days

    Other: Placebo

  • Other
    Open Label Extension LYT-100

    Open Label Extension: LYT-100 taken orally BID for 91 days The Open Label Extension (Part B) was terminated after results of the Double Blind Portion.

    Drug: LYT-100

Interventions

  • oral administration

    Also known as: Deupirfenidone

  • OtherPlacebo

    oral administration

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Distance Walked During the Six-Minute Walk Test (6MWT)

    The 6MWT is a validated endpoint commonly used in clinical trial research. The 6MWT measures the distance a subject can quickly walk on a flat, hard surface in a period of 6 minutes. It evaluates the global and integrated response of all the systems involved during exercise.

    Time frame: Baseline to Day 91

07

Results

Posted Jun 23, 2026

Participant flow

Double-blind (Days 1 to 91)
Participant flow — Double-blind (Days 1 to 91)
MilestonePlaceboLYT-100
Started9095
Completed7773
Not completed1322
Withdrew: Adverse event411
Withdrew: Lost to follow-up11
Withdrew: Physician decision01
Withdrew: Study terminated by sponsor13
Withdrew: Withdrawal by subject63
Withdrew: Other-reason not available13
Open-label Extension (Days 92 to 182)
Participant flow — Open-label Extension (Days 92 to 182)
MilestonePlaceboLYT-100
Started6047
Completed4129
Not completed1918
Withdrew: Adverse event56
Withdrew: Lost to follow-up01
Withdrew: Study terminated by sponsor109
Withdrew: Withdrawal by subject02
Withdrew: Other - reason not available40

Outcome measures

PrimaryChange From Baseline in Distance Walked During the Six-Minute Walk Test (6MWT)

The 6MWT is a validated endpoint commonly used in clinical trial research. The 6MWT measures the distance a subject can quickly walk on a flat, hard surface in a period of 6 minutes. It evaluates the global and integrated response of all the systems involved during exercise.

Time frame:
Baseline to Day 91
Reported as:
Least squares mean · meters
Change From Baseline in Distance Walked During the Six-Minute Walk Test (6MWT)
metersPlaceboLYT-100
Change From Baseline in Distance Walked During the Six-Minute Walk Test (6MWT)48.77 ± 9.99744.28 ± 9.948
Statistical analysis
  • Placebo · Mixed Models Analysis · p = 0.698

Adverse events

Collected over Data for the Double-blind Part of the study was reported for Days 1 to 91. Data for the Open-label Part of the study was reported for Days 92 to 182.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/90 (1.1%)3/90 (3.3%)19/90 (21.1%)
LYT-1000/95 (0%)3/95 (3.2%)52/95 (54.7%)
Open Label Extension LYT-1000/107 (0%)4/107 (3.7%)41/107 (38.3%)
Most frequent serious events
Most frequent serious events
EventPlaceboLYT-100Open Label Extension LYT-100
COVID-19Infections and infestations1/900/950/107
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/900/950/107
Abdominal painGastrointestinal disorders1/900/950/107
PneumoniaInfections and infestations0/901/950/107
AppendicitisInfections and infestations0/901/950/107
Mixed dementiaNervous system disorders0/901/950/107
Hypertension/Vascular disorders0/900/951/107
Drug eruptionSkin and subcutaneous tissue disorders0/900/951/107
LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/900/951/107
Hepatitis viralInfections and infestations0/900/951/107
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlaceboLYT-100Open Label Extension LYT-100
NauseaGastrointestinal disorders1/909/953/107
DyspepsiaGastrointestinal disorders1/906/955/107
HyperglycaemiaMetabolism and nutrition disorders5/903/954/107
Abdominal Pain UpperGastrointestinal disorders2/905/951/107
NasopharyngitisInfections and infestations1/905/953/107
Fibrin D Dimer IncreasedInvestigations1/905/952/107
HeadacheNervous system disorders2/905/953/107
CoughRespiratory, thoracic and mediastinal disorders0/905/954/107
RashSkin and subcutaneous tissue disorders1/904/954/107
COVID-19Infections and infestations2/902/954/107

Baseline characteristics

Information presented is based on the Intent to Treat (ITT) population which differs from the Safety Population presented in the participant flow. Please see Statistical Analysis Plan (SAP)

Age, Continuous
Age, Continuous(years)PlaceboLYT-100Total
Mean52.7 ± 12.4956.6 ± 12.1454.7 ± 12.43
Age, Customized
Age, Customized(Participants)PlaceboLYT-100Total
<65 years6769136
>=65 years182341
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLYT-100Total
Female353267
Male5060110
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboLYT-100Total
Hispanic or Latino81018
Not Hispanic or Latino7682158
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboLYT-100Total
American Indian or Alaska Native000
Asian201030
Native Hawaiian or Other Pacific Islander000
Black or African American213
White6179140
More than one race000
Unknown or Not Reported224
Region of Enrollment
Region of Enrollment(participants)PlaceboLYT-100Total
Argentina5813
Romania232548
United States111728
Philippines17825
Ukraine142034
Brazil022
United Kingdom325
Moldova121022
Weight
Weight(kg)PlaceboLYT-100Total
Mean85.45 ± 17.887.82 ± 16.9986.68 ± 17.375
Height
Height(cm)PlaceboLYT-100Total
Mean169.24 ± 10.178170.68 ± 9.858169.99 ± 10.01

3 further baseline measures are reported on the registry.

08

Study locations

31 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • North Alabama Medical Center
    Florence, Alabama 35630, United States
  • University of Southern California - Keck School of Medicine
    Los Angeles, California 90033, United States
  • Vista Health Research
    Miami, Florida 33176, United States
  • Central Florida Pulmonary Group
    Orlando, Florida 32803, United States
  • Coastal Pulmonary and Critical Care
    St. Petersburg, Florida 33704, United States
  • Tampa General Hospital
    Tampa, Florida 33606, United States
  • Center for Advanced Research and Education
    Gainesville, Georgia 30501, United States
  • GenHarp Clinical Solutions
    Evergreen Park, Illinois 60805, United States
  • Circuit Clinical/Crystal Run Healthcare LLP
    Middletown, New York 10941, United States
  • Southeastern Research Center
    Winston-Salem, North Carolina 27103, United States
  • University of Pittsburg Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Affinity Health Corp
    Nashville, Tennessee 37203, United States
  • Frostwood Family Medicine
    Houston, Texas 77024, United States
  • The University of Texas Health Sciences Center at San Antonio
    San Antonio, Texas 78229, United States
  • Clinica Central S.A
    Villa Regina, Río Negro Province 8336, Argentina
  • Fundacion Estudios Clinicos
    Rosario, Santa Fe Province 2000, Argentina
  • Investigaciones en Patologias Respiratorias
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • CETI - Centro de Estudos em Terapias Inovadoras
    Curitiba, Paraná 80030-110, Brazil
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Instituto de Doencas do Torax
    Rio de Janeiro, 21941-913, Brazil
  • PMSI Republican Clinical Hospital "T. Mosneaga"
    Chisinau, 2025, Moldova
  • University of the Philippines Manila - Philippine General Hospital (PGH)
    Manila, 1000, Philippines
  • Quirino Memorial Medical Center (QMMC)
    Quezon City, 1109, Philippines
  • National Institute for Infectious Diseases "Prof. Dr. Matei Balş" (Arensia Eploratory Medicine)
    Bucharest, Romania
  • Spitalul Clinic De Pneumoftiziologie "Leon Daniello" Cluj-Napoca
    Cluj-Napoca, 400332, Romania
  • Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr. Victor Babes Craiova
    Craiova, 200515, Romania
  • Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr. Victor Babes - Timisoara
    Timișoara, 300310, Romania
  • Medical Center of Limited Liability Company "Harmoniya krasy"
    Kiev, 01135, Ukraine
  • Guy's and St Thomas' NHS Foundation Trust - St Thomas' Hospital
    London, SE1 9RT, United Kingdom
  • St George's University Hospitals NHS Foundation Trust - St George's Hospital
    London, SW17 0QT, United Kingdom
09

References and documents

Publications

  • Kulkarni T, Santiaguel J, Aul R, Harnett M, Krop J, Chen MC, Graham CS, Maher TM. Deupirfenidone (LYT-100) in post-acute sequelae of SARS-CoV-2 with respiratory complications. ERJ Open Res. 2025 Jul 21;11(4):01142-2024. doi: 10.1183/23120541.01142-2024. eCollection 2025 Jul. PubMed 40692836 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Jun 2022, 18 months.

Results were first posted in Jun 2026, 3 years 11 months after primary completion. A results delay was requested in Jun 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2020
First posted
Dec 3, 2020
StartActual
Dec 11, 2020
Primary completionActual
Jun 28, 2022
CompletionActual
Jul 18, 2022
Results delay requested
Jun 28, 2023
Results first posted
Jun 23, 2026
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04652518
Lead sponsor
PureTech
Collaborators
Clinipace Worldwide, Novotech (Australia) Pty Limited
Responsible party
Sponsor
First posted
Dec 3, 2020
Start date
Dec 11, 2020
Primary completion
Jun 28, 2022
Completion
Jul 18, 2022
Results posted
Jun 23, 2026
Last update
Jun 23, 2026

Study contacts

Toby Maher, MD
principal investigator · Keck School of Medicine, University of Southern California

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirfenidone

Start the discussion